1302579-22-1

Basic information

• Product Name: (S)-2,2-dimethyl-4-[(E)-2-(4-nitrophenyl)vinyl]oxazolidine-3-carboxylic acid tert-butyl ester
• Synonyms: (S)-2,2-dimethyl-4-[(E)-2-(4-nitrophenyl)vinyl]oxazolidine-3-carboxylic acid tert-butyl ester
• CAS NO: 1302579-22-1
• Molecular Weight: 348.399
• Mol File: 1302579-22-1.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: (S)-2,2-dimethyl-4-[(E)-2-(4-nitrophenyl)vinyl]oxazolidine-3-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2,2-dimethyl-4-[(E)-2-(4-nitrophenyl)vinyl]oxazolidine-3-carboxylic acid tert-butyl ester(1302579-22-1)
• EPA Substance Registry System: (S)-2,2-dimethyl-4-[(E)-2-(4-nitrophenyl)vinyl]oxazolidine-3-carboxylic acid tert-butyl ester(1302579-22-1)

Safety Data

• Hazardous Substances Data: 1302579-22-1(Hazardous Substances Data)

Upstream product

• 108149-60-6 methyl [(4R)-3-(tert-butoxycarbonyl)-2,2-dimethyl-1,3-oxazolidin-4-yl]carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 136703-59-8 (3S)-3-[(tert-butoxycarbonyl)amino]-4-hydroxybutanoic acid methyl ester 
• 3145-86-6 4-nitrobenzyl iodide 
• 619-73-8 4-nitrobenzyl chloride 
• 555-16-8 4-nitrobenzaldehdye 
• 73805-86-4 [(p-nitrophenyl)methyl]triphenylphosphonium iodide 
• 95715-87-0 (R)-3-tert-butoxycarbonyl-4-formyl-2,2-dimethyloxazolidine 
• 108149-63-9 tert-butyl (4S)-4-(hydroxymethyl)-2,2-dimethyl-1,3-oxazolidine-3-carboxylate 
• 2609-49-6 diethyl p-nitrobenzylphosphonate 

Downstream Products

• 1302579-13-0 N-{4-[2-((S)-2-amino-4,5-dihydro-oxazol-4-yl)-ethyl]-phenyl}-4-chloro-benzamide 
• 1302579-15-2 (S)-4-{2-[4-(4-chloro-benzoylamino)-phenyl]-ethyl}-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester 
• 1357267-35-6 N-[4-((S)-3-amino-4-hydroxy-butyl)-phenyl]-4-chloro-benzamide 
• 1374037-60-1 (S)-2-amino-4-[4-(5-trifluoromethyl-pyridin-2-ylamino)-phenyl]-butan-1-ol 
• 1374037-59-8 (S)-2,2-dimethyl-4-{2-[4-(5-trifluoromethyl-pyridin-2-ylamino)-phenyl]-ethyl}-oxazolidine-3-carboxylic acid tert-butyl ester 
• 1374037-53-2 (S)-2-amino-4-[4-(4-chloro-phenylamino)-phenyl]-butan-1-ol 
• 1374037-52-1 (S)-4-{2-[4-(4-chloro-phenylamino)-phenyl]-ethyl}-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester 
• 1374037-51-0 (S)-4-{2-[4-(4-chloro-phenylamino)-phenyl]-ethyl}-4,5-dihydro-oxazol-2-ylamine 
• 1374038-22-8 (S)-4-(2-{4-[1-(5-bromo-pyridin-2-yl)-2,2,2-trifluoro-ethylamino]-phenyl}-ethyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester 
• 1302580-00-2 isoquinoline-5-sulfonic acid [4-((S)-3-amino-4-hydroxy-butyl)-phenyl]-amide 
• 1302579-98-1 isoquinoline-5-sulfonic acid {4-[2-((S)-2-amino-4,5-dihydro-oxazol-4-yl)-ethyl]-phenyl}-amide 
• 1302580-05-7 2-methoxy-pyrimidine-5-carboxylic acid {4-[2-((S)-2-amino-4,5-dihydro-oxazol-4-yl)-ethyl]-phenyl}-amide 
• 1302580-07-9 (S)-4-[(E)-2-(4-nitro-phenyl)-vinyl]-4,5-dihydro-oxazol-2-ylamine 
• 1302579-56-1 (S)-4-[2-(4-amino-phenyl)-ethyl]-4,5-dihydro-oxazol-2-ylamine 

Relevant articles and documents

Synthesis of a novel series of 2,3,4-trisubstituted oxazolidines designed by isosteric replacement or rigidification of the structure and cytotoxic evaluation

We have previously reported on a study of the structure-activity relationship in a series of 2,3,4-substituted oxazolidines recently discovered by our group varying the substituent at the ring or stereochemistry of the oxazolidine ring. We discovered the cytotoxic and pro-apoptotic potential of compounds 1 and 2 with good selectivity against cancer cell lines. In the present study we describe the synthesis and cytotoxic evaluation against cancer cell lines (HL60, JURKAT, MDA-MB-231 and LNCaP) of a series of oxazolidines designed by isosteric replacement or rigidification of the oxymethylene spacer of compounds 1 and 2. Alkenes 3 and 4 retained the activity against MDA-MB-231 cells and they were more active on HL60, JURKAT and LNCaP cells. Considering LNCaP cells, E-isomer 4 was at least 7 times and about 3 times more potent than lead 1 and Z-isomer 3, respectively. Compound 4 exerted significant activity against LNCaP with IC50 in the low micromolar range (11 μM) without affecting VERO cells and PBMC proliferation (IC50 > 100 μM) indicating its low toxicity to normal cells.

DIHYDROOXAZOL-2-AMINE DERIVATIVES

The invention relates to compounds of formula wherein R1, R2, R3, R4, X, Ar, and are defined herein or to a pharmaceutically suitable acid addition salt thereof. Compounds of formula I have a good affinity to th

PHARMACEUTICAL COMBINATION

The present invention relates to a pharmaceutical combination for the treatment of schizophrenia and acute manic episodes associated with bipolar disorders, which comprises a compound which is active on a trace amine-associated receptor 1 (TAAR1 agonist)